Abeona Therapeutics Inc. (ABEO) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low12.2·High12.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low2.4·High2.4
P/B Ratio
↑
2.40
↓-26% vs avg
5yr avg: 3.26
30Y Low0.3·High45.6
ROE
↑
70.0%
↓+155% vs avg
5yr avg: -127.8%
30Y Low-399%·High70%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low7.6·High7.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABEO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Abeona Therapeutics Inc. trades at 5.7x earnings, 9% above its 5-year average of 5.2x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 74%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $318M | $349M | $229M | $107M | $24M | $33M | $145M | $165M | $339M | $660M | $166M |
| Enterprise Value | $264M | $295M | $228M | $98M | $18M | $10M | $142M | $43M | $351M | $522M | $97M |
| P/E Ratio → | 5.71 | 5.22 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 54.57 | 59.89 | — | 30.60 | 17.13 | 11.16 | 14.55 | — | 113.18 | 788.24 | 186.44 |
| P/B Ratio | 2.40 | 2.19 | 5.19 | 7.22 | 0.90 | 0.79 | 1.42 | 0.92 | 2.53 | 3.88 | 1.67 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ABEO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 50.70 | — | 28.01 | 12.46 | 3.30 | 14.16 | — | 116.94 | 623.66 | 108.67 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ABEO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Abeona Therapeutics Inc. earns an operating margin of -1536.9%. Operating margins have compressed from -1346.7% to -1536.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 70.0% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.7% | 73.7% | — | 54.1% | 68.2% | 100.0% | 100.0% | — | -1190.8% | -1929.7% | -1098.5% |
| Operating Margin | -1536.9% | -1536.9% | — | -1346.7% | -3600.8% | -2994.5% | -814.2% | — | -1940.2% | -3325.7% | -2686.3% |
| Net Profit Margin | 1223.1% | 1223.1% | — | -1548.2% | -2807.4% | -2831.2% | -842.3% | — | -1890.3% | -3263.9% | -2460.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 70.0% | 70.0% | -216.6% | -260.6% | -114.8% | -117.2% | -60.0% | -48.8% | -37.3% | -20.3% | -26.2% |
| ROA | 43.3% | 43.3% | -73.7% | -84.5% | -55.2% | -73.6% | -45.0% | -38.4% | -32.1% | -18.9% | -22.9% |
| ROIC | -89.8% | -89.8% | -194.7% | -272.7% | -195.9% | -114.7% | -78.4% | -57.1% | -49.1% | -67.0% | -58.2% |
| ROCE | -63.4% | -63.4% | -89.9% | -88.1% | -85.3% | -104.3% | -55.4% | -45.5% | -35.6% | -20.2% | -26.3% |
ABEO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $78M exceeds total debt of $25M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.52 | 0.36 | 0.29 | 0.22 | 0.09 | 0.04 | 0.22 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.01 | -0.61 | -0.25 | -0.56 | -0.04 | -0.68 | 0.08 | -0.81 | -0.70 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -23.92 | -23.92 | -15.26 | -112.76 | -69.18 | -24.57 | -19.79 | -192.72 | -5287.82 | -3479.50 | -3980.17 |
Net cash position: cash ($78M) exceeds total debt ($25M)
ABEO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Abeona Therapeutics Inc.'s current ratio of 6.93x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.15x to 6.93x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.93 | 6.93 | 6.08 | 4.15 | 6.83 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Quick Ratio | 6.74 | 6.74 | 6.08 | 4.15 | 6.83 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Cash Ratio | 6.47 | 6.47 | 5.89 | 3.89 | 6.70 | 2.71 | 2.26 | 3.34 | 4.17 | 24.57 | 8.33 |
| Asset Turnover | — | 0.03 | — | 0.05 | 0.02 | 0.04 | 0.07 | — | 0.02 | 0.00 | 0.01 |
| Inventory Turnover | 0.28 | 0.28 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 421.13 | — | 254.87 | 48.53 | 365.00 | — | — | 9.86 | 46.66 | 50.91 |
ABEO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Abeona Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 17.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 17.5% | 19.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $66M | $41M | $21M | $8M | $4M | $4M | $2M | $2M | $2M | $1M |
Peer Comparison
Compare ABEO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABEOYou | $318M | 5.7 | — | — | 73.7% | -1536.9% | 70.0% | -89.8% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See ABEO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABEO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABEO vs KRYS
Side-by-side business, growth, and profitability comparison vs Krystal Biotech, Inc..
Start ComparisonABEO — Frequently Asked Questions
Quick answers to the most common questions about buying ABEO stock.
What is Abeona Therapeutics Inc.'s P/E ratio?
Abeona Therapeutics Inc.'s current P/E ratio is 5.7x. The historical average is 4.7x. This places it at the 100th percentile of its historical range.
What is Abeona Therapeutics Inc.'s ROE?
Abeona Therapeutics Inc.'s return on equity (ROE) is 70.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -120.7%.
Is ABEO stock overvalued?
Based on historical data, Abeona Therapeutics Inc. is trading at a P/E of 5.7x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Abeona Therapeutics Inc.'s profit margins?
Abeona Therapeutics Inc. has 73.7% gross margin and -1536.9% operating margin.